Lakewood-Amedex Biotherapeutics (Direct Listing)
Note: This is NOT an IPO. This is a public offering – a NASDAQ Direct Listing – of up to 4.7 million of our existing shares by our registered shareholders. The company also plans to sell 937,500 shares of Series C Preferred Stock to accredited investors for about $7.5 million. RBW Capital Partners is serving […]
April 3, 2026 Read More